Log in to search using one of your social media accounts:

 

Forsight Vision6 drums up another $3m
The sixth company to come out ophthalmology incubator ForSight Labs said today that it raised $3.0 million from a syndicate of nine unnamed investors. Stealthy ForSight Vision6 revealed the equity round in a regulatory filing today. The company added $3.0 million in December 2014 to the $1 million is raised in 20153 from a lone backer. Forsight Labs has a record of successful spinouts. In YYadte Allergan (NYSE: AGN) agreed to pay $95 million for ForSight Vision5 and its Helios drug-eluting ophthalmological implant, with a possible milestone payment for launching its drug-eluting device. The He...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Optical/Ophthalmic Wall Street Beat ForSight Vision Source Type: news

Coming Soon: Glaucoma Self-Care, From Home?
Study finds many patients can manage self-testing, but one doctor questions its value (Source: WebMD Health)
Source: WebMD Health - September 22, 2017 Category: Consumer Health News Source Type: news

Coming Soon: Glaucoma Self-Care, From Home?
FRIDAY, Sept. 22, 2017 -- For many glaucoma patients, repeat trips to a doctor's office to check on their eyes can be a real pain. But new research supports the usefulness of a device that allows glaucoma patients to measure their own eye pressure... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 22, 2017 Category: General Medicine Source Type: news

Coming Soon: Glaucoma Self-Care, From Home?
Title: Coming Soon: Glaucoma Self-Care, From Home?Category: Health NewsCreated: 9/22/2017 12:00:00 AMLast Editorial Review: 9/22/2017 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - September 22, 2017 Category: Opthalmology Source Type: news

How Well Can Glaucoma Patients Measure Their Own Intraocular Pressure? How Well Can Glaucoma Patients Measure Their Own Intraocular Pressure?
Self-measurement of intraocular pressure (IOP) by glaucoma patients is feasible and acceptable, but it remains to be seen whether it is sufficiently accurate to guide clinical management, according to an observational study.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 7, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Aerie launches Ph3 trial for Roclatan eye drug in Europe
Aerie Pharmaceuticals (NSDQ:AERI) said today that it launched its European Mercury 3 late-stage trial of Roclatan in patients with open-angle glaucoma or ocular hypertension. The eye drug is a fixed dose combination of Aerie’s Rhopressa netarsudil ophthalmic solution and a widely-used prostaglandin analogue, latanoprost. The company’s Phase III trial was designed to support regulatory approval and commercialization in Europe, Aerie said. Get the full story at our sister site, Drug Delivery Business News. The post Aerie launches Ph3 trial for Roclatan eye drug in Europe appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

Risk Factors for Rapid Glaucoma: Ophthalmology Times
(MedPage Today) -- Also, first-hand experience with extended depth of focus intraocular lenses (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 6, 2017 Category: American Health Source Type: news

FDA clears Second Sight IDE trial of next-gen Orion cortical visual prosthesis
Second Sight Medical (NSDQ:EYES) said today it won FDA investigational device exemption to initiate a feasibility clinical study of its Orion cortical visual prosthesis system. The conditional approval gives the Sylmar, Calif.-based company clearance to enroll up to 5 patients at 2 US sites, but requires that the company conduct additional device testing and “address outstanding questions” within 45 days, it said. “This is an exciting milestone for the company given the potential of Orion to provide useful vision to millions of blind individuals worldwide who have no other option today. We are deligh...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Prosthetics second-sight-medical Source Type: news

Efficacy of Gel Microstent for Primary Open-Angle Glaucoma Efficacy of Gel Microstent for Primary Open-Angle Glaucoma
Where does the gel microstent XEN ® fall among emerging devices and procedures for IOP reduction in primary open-angle glaucoma?Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2017 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Valeant ’s Tampa manufacturing plant on track for a better bill of health
The giant pharmaceutical company that owns a Tampa manufacturing plant that makes Bausch& Lomb products says it ’s on track to fix the problems at the facility that kept it from winning approval for a new glaucoma drug. The U.S. Food and Drug Administration has confirmed that issues related to a Good Manufacturing Practice inspection at the plant are being resolved, Joseph Papa, chairman and CEO of Valeant Pharmaceutical International Inc. (NYSE: VRX) said Wednesday. Valeant, based in Laval,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - August 17, 2017 Category: Health Management Authors: Margie Manning Source Type: news

Allergan gel-based stents are treating glaucoma
[Image from University of Michigan]An Allergan-developed gelatin-based stent is showing potential to treat glaucoma in a quicker and safer environment, according to new research from the University of Michigan. Glaucoma is a disease that damages the eye’s optic nerve and can cause vision loss and blindness. Medicines in the form of eyedrops or pills can be used to treat glaucoma. Another option is laser trabeculoplasty which helps drain fluid from the eye. Conventional surgery also creates a new opening in the eye for fluid to leave. Both surgical options are invasive and prone to complications. With the amount of gl...
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Stents Surgical Allergan Inc. Glaucoma MedTech Source Type: news

No Clear Differences in Shunts for Glaucoma (CME/CE)
(MedPage Today) -- Safety, efficacy similar to trabeculectomy (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 12, 2017 Category: Geriatrics Source Type: news

Working on a turnaround, Valeant gets a setback from its Bausch & Lomb plant in Tampa
Something is wrong at Valeant Pharmaceuticals International Inc. ’s Bausch& Lomb plant in Tampa. But Valeant (NYSE: VRX) isn’t detailing the nature of the problem that’s keeping it from moving forward with production of a new drug for glaucoma at the facility. “We are working to resolve manufacturing quality issues at our Tampa facility,” said Joseph Papa, Valeant chairman and CEO, d uring a conference call with analysts Tuesday. He was responding to questions about the “complete response… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 9, 2017 Category: American Health Authors: Margie Manning Source Type: news

Virtual Clinics in Glaucoma Care Virtual Clinics in Glaucoma Care
Do virtual clinics offer the same benefits to glaucoma patients as face-to-face assessments?The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2017 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Nigeria: 5,000 People Receive Free Eye Treatment
[Daily Trust] Dutse -Some 5,000 people have received free eye interventions that included surgeries for glaucoma and cataract as well as distribution of eye glasses in Birnin Kudu and Buji local government areas of Jigawa State. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 8, 2017 Category: African Health Source Type: news

$1.6 million grant to help African-Americans with glaucoma
(University of North Carolina at Chapel Hill) The University of North Carolina at Chapel Hill has received a grant worth nearly $1.6 million over four years from the Agency for Healthcare Research and Quality to help reduce vision problems in African-Americans caused by glaucoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2017 Category: International Medicine & Public Health Source Type: news

This tiny diaphragm pump could enable medical device innovation
Fraunhofer researchers have created a tiny yet powerful diaphragm pump that can deliver ambient air to gas sensors. The sensors are attached to a smartphone that warns a user of heavy exposure to particulate matter. “Our smart pump measures only 25 sq mm, making it the world’s smallest pump. That said, it still has a high compression ratio,” said Martin Richter, department head of microdosing systems at the Fraunhofer Research Institution for Microsystems and Solid State Technologies EMFT, in a press release. Richter also claims the pump could be used as a medical patch to continuously deliver small amoun...
Source: Mass Device - August 3, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Drug Pumps Research & Development fraunhofer MedTech Source Type: news

With $308M in cash, Duke spinout Aerie readying for commercialization
With roughly $308 million in cash and equivalents, Duke University spinout Aerie Pharmaceuticals (Nasdaq: AERI) is readying for commercialization, the company stated along with its second quarter financial results Tuesday. On the company's earnings call, Vicente Anido Jr., chairman and CEO of Aerie, stated that all of the company's programs – which consist of eye drop products for the treatment of glaucoma – are on track. A new drug application for Rhopressa has been accepted by the U.S. Food… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 2, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

Aerie inks deal for implantable drug-delivery system
Aerie Pharmaceuticals (NSDQ:AERI) said today that it inked a collaborative R&D and licensing agreement with DSM to develop an implantable drug-delivery system for patients with glaucoma and other retinal diseases. DSM has reportedly developed an injectable drug-delivery fiber using polyesteramide polymers that has proven successful in preclinical work with Aerie’s compounds. Get the full story at our sister site, Drug Delivery Business News.   The post Aerie inks deal for implantable drug-delivery system appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals dsm Source Type: news

Generic Eye Drops for Seniors Could Save Millions
Medicare is billed more than $1 billion annually for glaucoma treatments alone, researchers say (Source: WebMD Health)
Source: WebMD Health - July 28, 2017 Category: Consumer Health News Source Type: news

Generic Eye Drops for Seniors Could Save Millions of Dollars a Year
Medicare is billed more than $1 billion annually for glaucoma treatments alone, researchers saySource: HealthDay Related MedlinePlus Pages: Eye Diseases, Medicare Prescription Drug Coverage, Seniors' Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 28, 2017 Category: Consumer Health News Source Type: news

Generic Eye Drops for Seniors Could Save Millions of Dollars a Year
FRIDAY, July 28, 2017 -- Prescribing generic drugs for seniors'eye problems could save the U.S. government hundreds of millions of dollars a year, a new study suggests. Conditions like glaucoma and dry eye that require daily eye drops are common... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 28, 2017 Category: General Medicine Source Type: news

Risks of Steroid Use for Glaucoma
(MedPage Today) -- Ubiquitous steroid use posing unwitting cause for glaucoma (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 26, 2017 Category: American Health Source Type: news

Choose IOLs Wisely in Certain Patients: Ophthalmology Times
(MedPage Today) -- Also, exercise, diet and other factors may regulate glaucoma (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 26, 2017 Category: American Health Source Type: news

BioLight ’ s glaucoma insert succeeds in Phase I/IIa trial
BioLight Life Sciences (TLV:BOLT) touted data today from a Phase I/IIa clinical trial evaluating its Eye-D latanoprost insert. The device successfully lowered intraocular pressure during the study’s 12-week period and had a favorable safety profile, according to the Israel-based company. Get the full story at our sister site, Drug Delivery Business News. The post BioLight’s glaucoma insert succeeds in Phase I/IIa trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 24, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Research & Development Wall Street Beat biolightlifesciences Source Type: news

Glaucoma Dx Gets Computer Assist
(MedPage Today) -- Artificial intelligence will bring'reality'to glaucoma diagnosis (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - July 22, 2017 Category: Opthalmology Source Type: news

Aerie touts late-stage safety data for Roclatan eye drops
Aerie Pharmaceuticals (NSDQ:AERI) touted 12-month safety data yesterday from the Phase III registration trial of its Roclatan eye drops for intraocular pressure resulting from glaucoma or ocular hypertension. The study was designed to support Aerie’s new drug application submission to the FDA for Roclatan, which it expects to file in the first half of next year. Get the full story at our sister site, Drug Delivery Business News. The post Aerie touts late-stage safety data for Roclatan eye drops appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Aerie Pharmaceuticals Source Type: news

Coping with Advanced Glaucoma: Ophthalmology Times
(MedPage Today) -- Also, new drug delivery technologies in glaucoma (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 18, 2017 Category: American Health Source Type: news

UAB eye hospital to open clinic in growing community
Pell City and the surrounding counties will soon have a full-service eye care clinic. University of Alabama at Birmingham's Callahan Eye Hospital is opening a clinic July 24 that will provide specialized care. It will provide the same services the Birmingham site has offered for 50 years. The clinic will offer adult ophthalmology and optometry, pediatric optometry, eye exams, glas ses and contact lenses, cataract evaluations, glaucoma screenings, diabetic eye exams, dry eye testing and an optical… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 18, 2017 Category: Health Management Authors: Stephanie Rebman Source Type: news

Inotek recalibrates after drug fails in glaucoma trial
Inotek Pharmaceuticals (NSDQ:ITEK) said last week that its glaucoma drug failed in a Phase II trial. This marks the 2nd problem for Inotek’s drug this year, after it failed in a late-stage trial comparing it to a placebo in January. In response to the data, CEO David Southwell said in a statement that the company is assessing the future of its drug, trabodenoson, and “other strategic options.” Get the full story at our sister site, Drug Delivery Business News. The post Inotek recalibrates after drug fails in glaucoma trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 10, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat inotekpharmaceuticals Source Type: news

Inotek ’s trabodenoson shows no clinical advantage in Phase II FDC trial for glaucoma
Inotek Pharmaceuticals has reported top-line results from the Phase II fixed-dose combination (FDC) trial of trabodenoson and latanoprost in patients suffering from glaucoma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 9, 2017 Category: Pharmaceuticals Source Type: news

Gait implications of visual field damage from glaucoma - Mihailovic A, Swenor BK, Friedman DS, West SK, Gitlin LN, Ramulu PY.
PURPOSE: To evaluate fall-relevant gait features in older glaucoma patients. METHODS: The GAITRite Electronic Walkway was used to define fall-related gait parameters in 239 patients with suspected or manifest glaucoma under normal usual-pace walkin... (Source: SafetyLit)
Source: SafetyLit - July 8, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Lexington ’s Inotek suggests it could explore sale after another trial flop
Lexington-based Inotek Pharmaceuticals said Friday it is exploring “strategic alternatives” — corporate shorthand for a possible sale or other major transaction — after its lead drug for glaucoma flunked another big study. Inotek (Nasdaq: ITEK) announced the failure of a Phase 2 study in which patients received the company’s drug, called trabodenoson, al ong with another glaucoma eye drop, Pfizer’s Xalatan. According to Inotek, patients saw a reduction in eye pressure after four weeks… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 7, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Lexington ’s Inotek suggests it could explore sale after another trial flop
Lexington-based Inotek Pharmaceuticals said Friday it is exploring “strategic alternatives” — corporate shorthand for a possible sale or other major transaction — after its lead drug for glaucoma flunked another big study. Inotek (Nasdaq: ITEK) announced the failure of a Phase 2 study in which patients received the company’s drug, called trabodenoson, al ong with another glaucoma eye drop, Pfizer’s Xalatan. According to Inotek, patients saw a reduction in eye pressure after four weeks… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 7, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Refractive Surgery in the Glaucoma Patient Refractive Surgery in the Glaucoma Patient
Find out what there is to know about the appropriate management of glaucoma patients undergoing refractive surgery.Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 30, 2017 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Arkansas to Accept Medical Marijuana Card Applications
LITTLE ROCK — Arkansas' medical marijuana industry will ramp up in the next week, with the state poised to accept applications from potential patients, growers and distributors. Beginning Friday, the state Medical Marijuana Commission will accept applications from those hoping to grow or supply marijuana, while the Health Department will take applications from those hoping to benefit from the first marijuana-as-medicine program in the Bible Belt. The application periods will run until Sept. 18. State officials expect anywhere from 20,000 to 40,000 people to seek permission to use the drug for a number of health probl...
Source: Arkansas Business - Health Care - June 26, 2017 Category: American Health Source Type: news

Gap Junctions (GJs) and Glaucoma
This study references use of ourGFAP Antibody,Gap junctions (GJs), intercellular channels composed of subunit connexins, can play a major role in secondary cell death by forming conduits through which toxic molecules from dying cells pass to and injure coupled neighbors. Secondary cells like glia and astrocytes are involved in this process though the precise mechanisms have yet to be defined: Abram Akopian, Sandeep Kumar, Hariharasubramanian Ramakrishnan, Kaushambi Roy, Suresh Viswanathan, and Stewart A. Bloomfield.Targeting neuronal gap junctions in mouse retina offers neuroprotection in glaucoma. J Clin Invest. doi:10.11...
Source: Neuromics - June 21, 2017 Category: Neuroscience Tags: Astrocyte Marker Gap Junctions GFAP Antibody Glaucoma Glial Fibrillary Acidic Protein Antibody Glial Markers Neuronal Markers Source Type: news

Real Stories Of Americans Who Will Be Affected By The Proposed Changes To The ACA — And What YOU Can Do To Fight
With the proposed changes to the Affordable Care Act (ACA), 20 million Americans are at risk of losing their health care coverage. A survey, conducted by Brunswick Partners, found that “75 percent of Americans agree that the proposed changes to Medicaid in the AHCA are a bad idea. And that we should not allow 14 million Americans to become uninsured even if there is a potential to reduce Medicaid spending. These results are significant because they find majorities of Americans identifying as conservatives (55 percent), moderates (82 percent) and liberals (90 percent) are opposed to the AHCA’s Medicaid pro...
Source: Healthy Living - The Huffington Post - June 21, 2017 Category: Consumer Health News Source Type: news

Glaukos touts iStent study with topical travoprost
Glaukos (NYSE:GKOS) touted data today from a 53-patient glaucoma study showing that its iStent device combined with topical travoprost reduced mean intraocular pressure by 35% after 18 months of follow-up. The company’s flagship device is designed to lessen IOP by restoring the natural outflow of aqueous humor through the conventional pathway in a patient’s eye. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts iStent study with topical travoprost appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Stents Wall Street Beat Glaukos Source Type: news

Tisbury Pharmaceuticals Launches with a USD 32 Million Series A...
Investment proceeds to be used to develop Tisbury's proprietary glaucoma compound, R-801(PRWeb June 14, 2017)Read the full story at http://www.prweb.com/releases/2017/06/prweb14418503.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2017 Category: Pharmaceuticals Source Type: news

Blind prevention: It's as important to check THIS pressure as it is blood pressure
BLINDNESS is often caused by glaucoma, but the eye condition can be caught early by getting your eye pressure tested - just like your blood pressure. (Source: Daily Express - Health)
Source: Daily Express - Health - June 13, 2017 Category: Consumer Health News Source Type: news

Nigeria: NAF Equips Hospitals for Early Detection of Glaucoma
[Daily Trust] Kaduna -The Chief of the Air Staff, Air Marshal Sadique Abubakar has expressed the worry that in Nigeria, glaucoma is the second commonest cause of blindness at 16.7% after cataract. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - June 8, 2017 Category: African Health Source Type: news

Does Your Pet Need an Eye Doctor?
Veterinarians specialized in vision problems are few, but some conditions ailing dogs and other animals can be treated. (Source: NYT Health)
Source: NYT Health - June 6, 2017 Category: Consumer Health News Authors: SUSAN JENKS Tags: Eyes and Eyesight Dogs Cats Cataracts Genetics and Heredity Foxes Veterinary Medicine Surgery and Surgeons Transplants Pets Glaucoma Corneas Blindness Doctors Genetic Engineering Source Type: news

Glaucoma laser developer Belkin Laser raises $5m
Ophthalmological device developer Belkin Laser has closed a $5.3 million round of financing, according to a Globes Israel report. The funding round was comprised of $2.5 million from Zico Holdings and Rimonci Capital and $2.8 million (EU €2.5 million) in an EU grant as part of the GLAUrious Program, which was initiated by Belkin Laser and 4 collaborative European partners. The Israel-based company, which was spun out of the RAD Biomed accelerator, is developing a laser device designed to treat patients with glaucoma to replace eye drops that are currently standard of care, according to the report. The device is based ...
Source: Mass Device - June 5, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic belkinlaser Source Type: news

7 medtech stories we missed this week: June 2, 2017
[Photo from unsplash.com]From Implandata receiving CE Marking to Inolife eyeing up-listing, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Dextera seeks expanded indications for MicroCutter 5/80 stapler Dextera Surgical announced in a June 1 press release that it has filed a 510(k) with the FDA for its MicroCutter 5/80 stapler. The company wants to expand the indications of the MicroCutter 5/80 for use in liver, pancreas, kidney and spleen surgeries. Currently, the staplers are used for transection and resection in multiple open minimally-invasive urologic, thoracic and...
Source: Mass Device - June 2, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Business/Financial News Clinical Trials News Well Regulatory/Compliance Research & Development c2 Therapeutics Dextera Surgical DreaMed Diabetes EndoGastric Solutions Inc. Implandata Inolife MicroTransponder Inc. Source Type: news

Eyeing the Death of a Cell
(MedPage Today) -- Researchers image single cell deaths in glaucoma patients (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - June 1, 2017 Category: Opthalmology Source Type: news

For Monitoring Glaucoma, OCT Bests Visual Field Testing For Monitoring Glaucoma, OCT Bests Visual Field Testing
Optical coherence tomography (OCT) is more sensitive than visual field (VF) testing at detecting progression in early glaucoma, new research reports.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 31, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Cognitive Decline, Increased Visual-Field Variability in Glaucoma Cognitive Decline, Increased Visual-Field Variability in Glaucoma
Cognitive decline is associated with increased visual-field variability over time in patients with glaucoma, suggesting a need to screen and monitor for cognitive dysfunction, according to a new study.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - May 31, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Stocks rise for Aerie, BioCryst following positive trial results
Duke University spinout Aerie Pharmaceuticals ’ (Nasdaq: AERI) as well as Durham-based BioCryst Pharmaceuticals (Nasdaq: BCRX) both saw stock prices jump Thursday on the heels of positive trial results. Shares of both companies were up about 30 percent Thursday afternoon, with shares of Aerie trading just under $53 and shares of BioCryst tra ding close to $7. Late Wednesday, Aerie announced positive Phase 2 trial results for glaucoma product Roclatan. Vicente Anido Jr., chairman and CEO of Aerie,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 25, 2017 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

College of Optometrists announces new accreditation of professional diploma in glaucoma
Moorfields Eye Hospital and the UCL Institute of Ophthalmology have been accredited as a provider of the professional diploma in glaucoma by the College of Optometrists. (Source: NHS Networks)
Source: NHS Networks - May 25, 2017 Category: UK Health Source Type: news